Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes

Sheldon W Tobe¹, Stephanie Poon^{2

3}

Affiliations

¹ Northern Ontario School of Medicine, Toronto, ON, Canada (S.W.T.).
² Division of Cardiology, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada (S.P.).
³ Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada (S.P.).

Editorial

Sheldon W Tobe et al. Circulation. 2020.

. 2020 Sep 29;142(13):1246-1248.

doi: 10.1161/CIRCULATIONAHA.120.050398. Epub 2020 Sep 28.

Sheldon W Tobe¹, Stephanie Poon^{2

3}

¹ Northern Ontario School of Medicine, Toronto, ON, Canada (S.W.T.).
² Division of Cardiology, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada (S.P.).
³ Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada (S.P.).

No abstract available

Keywords: Editorials; drug therapy; heart failure; humans; neprilysin.

Comment on

Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.
Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, Jhund PS, McGrath MM, Packer M, Shi V, Van Veldhuisen DJ, Zannad F, Comin-Colet J, Pfeffer MA, McMurray JJV, Solomon SD. Mc Causland FR, et al. Circulation. 2020 Sep 29;142(13):1236-1245. doi: 10.1161/CIRCULATIONAHA.120.047643. Epub 2020 Aug 17. Circulation. 2020. PMID: 32845715 Clinical Trial.